Rosuvastatin Interactions: A Complete Evidence-Based Guide

Rosuvastatin is a commonly prescribed cholesterol-lowering medication, but it has several documented serious interactions—particularly with antiviral and protease inhibitor medications used to treat HIV and hepatitis C. According to FDA drug labels, rosuvastatin should not be used with certain HIV protease inhibitors, hepatitis C antivirals, and other statin medications without careful dose adjustment and medical supervision. This guide explains the source-documented interactions, what they mean for your safety, and how to discuss them with your healthcare provider.

What Is Rosuvastatin?

Rosuvastatin is a statin, a class of medications that lowers cholesterol by blocking an enzyme (HMG-CoA reductase) in the liver. Statins are among the most widely prescribed medications for preventing heart disease and stroke. Rosuvastatin is available under the brand name Crestor and as a generic medication. It comes in various doses, typically ranging from 5 mg to 40 mg daily, though dose adjustment is often necessary depending on kidney function and other factors.

Statins work primarily through the liver, where they are metabolized (broken down) by the body. When other medications interfere with this metabolism, or when multiple cholesterol-lowering drugs are combined without proper adjustment, the concentration of rosuvastatin in your bloodstream can rise to harmful levels. This is the central concern in documented rosuvastatin interactions.

Most Serious Documented Interactions: Protease Inhibitors

The most extensively documented serious interactions involve protease inhibitors—a class of antiviral medications used primarily in HIV treatment. FDA drug labels for ritonavir, darunavir, lopinavir/ritonavir, and cobicistat all carry explicit contraindication warnings about rosuvastatin.

Ritonavir (NORVIR)

According to the FDA drug label for ritonavir 100 mg, concurrent use with rosuvastatin is contraindicated due to the potential for myopathy (muscle disease) including rhabdomyolysis (a serious muscle-breakdown condition). The label provides no mechanism explanation in the supplied source record, but the contraindication is unqualified: co-administration should not occur. If a patient requires both an HIV protease inhibitor regimen that includes ritonavir and cholesterol management, alternative statins and alternative HIV regimens should be considered in consultation with an HIV specialist and cardiologist.

Darunavir

Darunavir, another widely used HIV protease inhibitor, presents similar documented contraindications across multiple formulations. FDA labels for darunavir 600 mg, darunavir ethanolate and cobicistat, and darunavir (general) all state that concurrent rosuvastatin use is contraindicated due to potential for serious reactions such as myopathy including rhabdomyolysis. When rosuvastatin must be used with darunavir-containing regimens, the FDA guidance in the supplied labels indicates that rosuvastatin dosage should be carefully titrated and not exceed 20 mg/day, though this represents a cautious approach rather than a recommendation for concurrent use.

Lopinavir and Ritonavir (KALETRA)

The fixed-dose combination lopinavir/ritonavir carries a contraindication for concurrent rosuvastatin use, with a more restrictive dose ceiling than darunavir: if rosuvastatin is unavoidable, the dose should not exceed 10 mg/day. This is one of the strongest dose restrictions in the supplied records, reflecting heightened concern about drug accumulation with this particular protease inhibitor combination.

Cobicistat (TYBOST)

Cobicistat, a pharmacokinetic booster used with HIV protease inhibitors, also interacts with rosuvastatin. The FDA label for cobicistat specifies different dose restrictions depending on which protease inhibitor it is paired with: when cobicistat is given with atazanavir, rosuvastatin should not exceed 10 mg/day; when cobicistat is given with darunavir, rosuvastatin should not exceed 20 mg/day. The label notes that coadministration of atazanavir and cobicistat with atorvastatin (a different statin) is not recommended—underscoring that protease inhibitor combinations often present broader statin class challenges.

Documented Interactions with Hepatitis C Antivirals

Two hepatitis C antiviral combinations carry contraindications with rosuvastatin due to increased rosuvastatin exposure (elevated blood concentration of the drug):

Sofosbuvir, Velpatasvir, and Voxilaprevir

According to source material from the rosuvastatin labeling domain, the three-drug hepatitis C combination sofosbuvir, velpatasvir, and voxilaprevir increases rosuvastatin exposure significantly. Use with rosuvastatin tablets is not recommended. If a patient with hepatitis C and high cholesterol requires concurrent treatment, alternative cholesterol-lowering agents should be discussed with both the hepatologist and cardiologist.

Ledipasvir and Sofosbuvir

The two-drug hepatitis C combination ledipasvir and sofosbuvir may significantly increase rosuvastatin exposure. Concomitant use with rosuvastatin is not recommended according to FDA source material. Again, alternative approaches to cholesterol management during hepatitis C treatment should be explored.

Documented Interactions with Other Statins and Lipid-Modifying Agents

FDA drug labels for protease inhibitors consistently warn about concurrent use of multiple statins. The supplied records indicate that when rosuvastatin is used with other HMG-CoA reductase inhibitors (such as atorvastatin, fluvastatin, pravastatin, or pitavastatin), the risk of serious adverse effects increases. The mechanism is not specified in the supplied source records, but the documented concern is myopathy and rhabdomyolysis.

When multiple statins must be used together (a rare clinical scenario), the FDA guidance emphasizes starting with the lowest recommended dose and titrating carefully while monitoring for safety. For example, when atorvastatin is combined with certain protease inhibitors, atorvastatin should not exceed 20 mg/day; similarly, rosuvastatin under those conditions should not exceed 20 mg/day.

Additionally, the microsomal triglyceride transfer protein (MTTP) inhibitor lomitapide is contraindicated with rosuvastatin. According to FDA drug labels for ritonavir, darunavir, and lopinavir/ritonavir, concurrent use of rosuvastatin and lomitapide is contraindicated due to potential for markedly increased liver enzyme levels (transaminases) and myopathy including rhabdomyolysis. Lomitapide is a rarely used specialist lipid-modifying agent; most patients will not encounter this combination, but it is important to disclose all lipid-modifying medications to your pharmacist.

Understanding the Severity and Mechanism

All documented rosuvastatin interactions in the supplied source records carry a contraindication designation—the most serious warning level in FDA labeling. Contraindication means that co-administration is generally not recommended except in carefully selected circumstances where the benefit may outweigh the risk, and only under close medical supervision.

The supplied FDA source records do not provide detailed mechanistic explanations for most of these interactions. However, the consistent warning across protease inhibitors and hepatitis C antivirals suggests that these medications interfere with rosuvastatin metabolism or excretion, causing the drug to accumulate in the body to dangerous levels. When rosuvastatin concentration becomes too high, muscle toxicity (myopathy) and severe liver enzyme elevation become risks. The most feared outcome is rhabdomyolysis, a condition in which muscle tissue breaks down rapidly, releasing proteins that can damage the kidneys and cause kidney failure.

Hypothetical Examples: How These Interactions Matter in Practice

Hypothetical Scenario 1: HIV and Cholesterol Management

Imagine a patient newly diagnosed with HIV who is started on darunavir-based therapy. The same patient has a history of high cholesterol and heart disease risk. The prescribing physician knows that rosuvastatin is an excellent choice for this patient's lipid profile. However, because darunavir is contraindicated with rosuvastatin (according to FDA labeling), the physician must choose an alternative statin that has a better safety profile with protease inhibitors, or use a different HIV regimen altogether. This requires coordination between the HIV specialist and the cardiologist. The interaction is not just a theoretical concern—it reflects documented cases of statin-related muscle injury in patients taking protease inhibitor combinations.

Hypothetical Scenario 2: Dose Adjustment Under Necessary Co-Use

In rare cases where rosuvastatin cannot be avoided with a protease inhibitor (for example, if a patient has already stabilized on both drugs and switching is clinically inadvisable), the FDA guidance in the supplied labels specifies strict dose limits. If a patient were already on rosuvastatin 40 mg and was prescribed darunavir, the rosuvastatin dose would need to be reduced to no more than 20 mg/day. If darunavir were combined with lopinavir/ritonavir, the limit would be even lower—10 mg/day. These dose reductions are intentionally conservative to minimize the risk of accumulation and myopathy.

Documented Rosuvastatin Interactions—Summary

• Ritonavir: Contraindicated—risk of myopathy and rhabdomyolysis. No safe co-use guidance provided in supplied FDA labels.
• Darunavir (all formulations): Contraindicated—risk of myopathy and rhabdomyolysis. If unavoidable, rosuvastatin should not exceed 20 mg/day with careful monitoring.
• Lopinavir and Ritonavir (KALETRA): Contraindicated—risk of myopathy and rhabdomyolysis. Most restrictive guidance: rosuvastatin should not exceed 10 mg/day if essential.
• Cobicistat (TYBOST): Dose-dependent contraindication. With atazanavir: rosuvastatin not to exceed 10 mg/day. With darunavir: rosuvastatin not to exceed 20 mg/day.
• Sofosbuvir, Velpatasvir, and Voxilaprevir: Contraindicated—significantly increased rosuvastatin exposure. Use with rosuvastatin tablets is not recommended.
• Ledipasvir and Sofosbuvir: Not recommended for concurrent use—significant increase in rosuvastatin exposure documented.
• Other statins (atorvastatin, fluvastatin, pravastatin, pitavastatin): Risk of serious myopathy when combined with rosuvastatin in protease inhibitor regimens. Lowest doses required with careful monitoring.
• Lomitapide: Contraindicated—risk of markedly increased liver enzymes and myopathy including rhabdomyolysis.

Questions to Ask Your Pharmacist or Physician

Before starting rosuvastatin or any of the medications listed above, use these questions to guide your conversation with your healthcare provider:

• Are you currently taking or about to start any HIV protease inhibitors (such as darunavir, ritonavir, lopinavir, or atazanavir)? If yes, discuss whether rosuvastatin is safe or if an alternative statin is needed.
• Are you being treated for hepatitis C? If yes, ask specifically whether your antiviral regimen (such as sofosbuvir-containing drugs) is compatible with rosuvastatin.
• Are you taking any other cholesterol-lowering medications, including other statins, ezetimibe, PCSK9 inhibitors, inclisiran, or lomitapide? Tell your doctor about all lipid-modifying agents.
• What dose of rosuvastatin are you on, and has your prescriber reviewed this dose in light of any other medications you take? If you are on a protease inhibitor or hepatitis C antiviral, confirm that your rosuvastatin dose complies with FDA guidance (typically 20 mg/day or lower).
• Have you experienced any unexplained muscle pain, weakness, or dark urine (signs of myopathy or rhabdomyolysis) since starting rosuvastatin or after a dose increase? Report these symptoms immediately.
• Are there any major changes in your kidney function, liver function, or medication list? These changes can affect how your body handles rosuvastatin and may require dose adjustment.

Key Takeaways

• Rosuvastatin has multiple FDA-documented contraindications with HIV protease inhibitors (ritonavir, darunavir, lopinavir/ritonavir, cobicistat) and hepatitis C antivirals (sofosbuvir/velpatasvir/voxilaprevir and ledipasvir/sofosbuvir). These are not theoretical warnings—they reflect documented risks of serious muscle injury and kidney damage.
• The primary safety concern is myopathy and rhabdomyolysis, muscle-breakdown conditions caused by elevated rosuvastatin levels in the blood when metabolism is impaired by concurrent medications.
• Dose adjustment is critical. If concurrent use is unavoidable, rosuvastatin doses are strictly limited: typically 10–20 mg/day maximum, well below standard therapeutic doses of 20–40 mg/day.
• Disclosure of all medications is essential. Even over-the-counter supplements and alternative lipid-modifying agents can interact with rosuvastatin. Your pharmacist needs a complete list to check for interactions.
• Do not adjust or stop rosuvastatin on your own. If you have concerns about interactions, contact your prescribing physician and pharmacist. They may recommend switching to a different statin, adjusting your HIV or hepatitis C regimen, or adding closer monitoring (such as liver enzyme or muscle enzyme blood tests).

Sources

• National Library of Medicine DailyMed: FDA-Approved Drug Labels – Source for all FDA drug label quotations in this article, including labels for ritonavir, darunavir, lopinavir/ritonavir, cobicistat, and rosuvastatin.
• NIH RxNorm Database – Authoritative source for drug names, RxCUI identifiers, and standardized drug information.
• U.S. FDA Open Data Portal – Access to official FDA drug safety and labeling information.
• PubMed Central – For independent verification of clinical evidence regarding statin interactions and adverse events.

Protect Your Health: Check Your Medications Today

If you are taking rosuvastatin along with any HIV medication, hepatitis C antiviral, or other lipid-modifying agent, you need to know whether that combination is safe. Visit checkdruginteractions.com right now to enter your complete medication list and check for documented interactions. Our tool is powered by FDA labeling and NIH data, so you can trust the results. Always confirm any changes to your medication regimen with your pharmacist or physician—do not make adjustments on your own. If your current combination appears in this guide or is flagged as contraindicated, your healthcare provider may recommend a dose adjustment, a medication switch, or additional monitoring. Taking action today can prevent serious complications.